MADISON, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that four Wyeth researchers were honored at the Research & Development (R&D) Council of New Jersey 2006 Annual Thomas Alva Edison Patent Awards last night for a significant scientific breakthrough and revolutionary product innovation originating in New Jersey. The Wyeth researchers, Christopher P. Miller, Ph.D.; Michael D. Collini; Bach D. Tran; and Arthrur A. Santilli, Ph.D., received the 2006 Thomas Alva Edison Patent Award in the category of Emerging Therapies. The researchers were granted the patent for bazedoxifene, an investigational selective estrogen receptor modulator for the prevention of postmenopausal osteoporosis.
Wyeth submitted a new drug application to the U.S. Food and Drug Administration in June 2006 for bazedoxifene as a potential new therapy for the prevention of postmenopausal osteoporosis.
“The R&D Council of New Jersey is acknowledging the advancement of a treatment that has the potential to improve the quality of life for postmenopausal women,” says Robert R. Ruffolo, Jr., Ph.D., President, Wyeth Research, and Senior Vice President, Wyeth. “Bazedoxifene is a significant component of the Wyeth pipeline, and we are grateful that our scientists are receiving this recognition from the R&D Council of New Jersey.”
The awards were presented at the R&D Council of New Jersey’s Annual Awards Dinner at the North Maple Inn, Basking Ridge, N.J., on November 2, 2006.
About the R&D Council of New Jersey
The Research & Development Council of New Jersey is a non-profit organization dedicated to cultivating an environment that supports the advancement of research and development throughout New Jersey. The council is composed of senior representatives from industry, academia and government. In fact, many R&D Council members represent today’s Fortune 100 companies. More information can be found on the council’s Web site: http://www.rdnj.org.
About Wyeth
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, RISK FACTORS.”
We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Wyeth
CONTACT: Gerald Burr of Wyeth Pharmaceuticals, +1-484-865-5138, or Media:Douglas Petkus, +1-973-660-5218, or Investors: Justin Victoria,+1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
